Literature DB >> 1283308

Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates.

G R Nakamura1, R Byrn, K Rosenthal, J P Porter, M R Hobbs, L Riddle, D J Eastman, D Dowbenko, T Gregory, B M Fendly.   

Abstract

Ten monoclonal antibodies prepared against a soluble, recombinant form of gp160, derived from the IIIB isolate of HIV-1, were characterized. Four of the antibodies neutralized HIV-1IIIB infectivity in vitro, three blocked the binding of recombinant gp120 to CD4, three were reactive with gp41, and one preferentially reacted with an epitope on gp120 within the gp160 precursor. All three CD4 blocking antibodies bound to distinct epitopes, with one mapping to the C1 domain, one mapping to the C4 domain, and one reactive with a conformation-dependent, discontinuous epitope. Of these, the antibody reactive with the discontinuous epitope exhibited neutralizing activity against homologous and heterologous strains of HIV-1. The binding of these monoclonal antibodies to a panel of seven recombinant gp120s prepared from diverse isolates of HIV-1 was measured, and monoclonal antibodies with broad cross reactivity were identified. The epitopes recognized by 7 of the 10 monoclonal antibodies studied were localized by their reactivity with synthetic peptides and with fragments of gp120 expressed as fusion proteins in a lambda gt-11 gp160 epitope library.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283308     DOI: 10.1089/aid.1992.8.1875

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  12 in total

1.  Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Authors:  Bin Yu; Dora P A J Fonseca; Sara M O'Rourke; Phillip W Berman
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

2.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.

Authors:  J P Moore; M Thali; B A Jameson; F Vignaux; G K Lewis; S W Poon; M Charles; M S Fung; B Sun; P J Durda
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

3.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

4.  Identification and CRISPR/Cas9 Inactivation of the C1s Protease Responsible for Proteolysis of Recombinant Proteins Produced in CHO Cells.

Authors:  Sophia W Li; Bin Yu; Gabriel Byrne; Meredith Wright; Sara O'Rourke; Kathryn Mesa; Phillip W Berman
Journal:  Biotechnol Bioeng       Date:  2019-06-10       Impact factor: 4.530

5.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.

Authors:  G R Nakamura; R Byrn; D M Wilkes; J A Fox; M R Hobbs; R Hastings; H C Wessling; M A Norcross; B M Fendly; P W Berman
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

7.  Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.

Authors:  D C Bou-Habib; G Roderiquez; T Oravecz; P W Berman; P Lusso; M A Norcross
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.

Authors:  G Roderiquez; T Oravecz; M Yanagishita; D C Bou-Habib; H Mostowski; M A Norcross
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.

Authors:  C Y Kang; K Hariharan; P L Nara; J Sodroski; J P Moore
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.